Here you will find the latest ESG and investor relations news, studies and press releases from cometis AG and our partner PRGN – Public Relations Global Network. With the capital market panel and the investor relations panel, cometis has been conducting studies on current market events in the areas of capital markets, ESG and investor relations for several years. To this end, cometis surveys experts from the respective departments several times a year on current topics. In this context, cometis evaluates the topics and the concept and is also responsible for conducting the study.
Here, you can go directly to the respective years of Investor Relations News:
May 21, 2019 | Dermapharm Holding SE: First quarter of 2019 characterized by profitable growth
Grünwald, May 21, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading producer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its report for the first three months of 2019 today, having increased its revenues by 19.0% to EUR 163.6 million (prior-year quarter: EUR 137.5 million). Earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for one-off costs of EUR 2.9 million in connection with the acquisition of the Spanish company Euromed and one-off costs of EUR 0.1 million for consulting services in connection with further acquisition efforts, increased by 20.7% to EUR 43.7 million (prior-year quarter: EUR 36.2 million). The adjusted EBITDA margin was 26.7%, 0.4 percentage points above the margin of the previous year. Unadjusted EBITDA amounted to EUR 40.7 million while the unadjusted EBITDA margin was 24.9%.